Biopharma correspondent at Endpoints. [email protected]
United States (National)
Not enough data
Not enough data
Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.
Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.
As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Andrew Dunn
David Baker has been pushing the limits of designing proteins for decades. The computational biologist started developing software, called Rosetta, to study and design proteins …
By: Andrew Dunn
FogPharma is renaming itself as Parabilis Medicines, announcing a new corporate identity Monday that reflects the imprint left by CEO Mathai Mammen since joining in …
By: Andrew Dunn
Iambic Therapeutics has used its AI models to build a pipeline and put its first drug candidate in the clinic earlier this year. Now, the …
By: Andrew Dunn
The newest David Baker biotech startup launched Wednesday, as Archon Biosciences has raised a $20 million seed round to develop what it believes could be …
By: Andrew Dunn
LONDON — Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic …
By: Andrew Dunn
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It …
By: Andrew Dunn
The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...
By: Andrew Dunn
A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the process of recruiting patients into clinical …
By: Andrew Dunn
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical drug programs.
By: Gene Tx
Less than a decade ago, a slew of startups like Metagenomi and Mammoth Biosciences raised huge sums of money …
(833) 317-6278 
